Following a GRAS (generally recognized as safe) notification for its Taxifolin BC-DHQ, Blue California’s has received a letter of no objection from FDA.
Photo © iStockphoto.com/Trout55
Following a GRAS (generally recognized as safe) notification for its Taxifolin BC-DHQ, Blue California’s (Rancho Santa Margarita, CA) has received a letter of no objection from FDA. Dihydroquercetin (DHQ), known as taxifolin, is a flavonoid commonly found in apples, olive oil, and red onions. As a flavonoid, taxifolin possesses antioxidant and anti-inflammatory properties that may support immune health.
“This GRAS status is good news for consumers and brands alike, because it opens new doors for brands to create products that will excite health-conscious consumers,” said Linda May-Zhang, PhD, research, science and innovation officer at Blue California, in a press release. “DHQ is a powerful antioxidant that has a greater antioxidant capacity when compared to vitamin C, and it is ideal in a variety of on-trend food applications, including beverages, yogurt and chocolate products.”
As an antioxidant, DHQ also has utility in foods and beverages, providing improved color stability for beverages, extended shelf life, and enhanced flavor, explains May-Zhang. “Not only is DHQ regarded as a promising ingredient to immune health, it may also be used in cosmetic applications for anti-aging and UV-protection,” she adds.
Blue California’s Taxifolin BC-DHQ is made with a sustainable process developed by innovation partner Conagen. Using its proprietary bioconversion process, Conagen was able to achieve clean, reliable, and scalable DHQ.
“Conagen is unlocking novel compounds from nature which are more sustainable and offer better options for ingredient applications, said Casey Lippmeier, PhD, vice president of innovation at Conagen. “Our ability to rapidly scale-up and commercialize this and other novel ingredient solutions demonstrates our strength as a strategic service partner.”
The impact of GLP-1 on supplements, functional foods, and retail: a webinar from CRN
January 29th 2025The recent CRN webinar discussed GLP-1 medications' impact on supplements, functional foods, and retail, covering consumer trends, global market insights, retailer strategies, industry implications, and future opportunities for innovation.